A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

From cycles 1-4, 1.3mg/m\^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle

From cycles 5-9, 1.3mg/m\^2 on days 1, 8, 22, and 29 of each 6-week cycle

9 mg/m\^2 once daily on days 1-4 of each 6-week cycle

60 mg/m\^2 once daily on days 1-4 of each 6-week cycle